Co-Diagnostics (NASDAQ: CODX) announced on March 20, 2026, that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. This expansion significantly increases CoSara's addressable market to an estimated $13.0 billion, according to the company's press release.
The expansion supports the planned commercialization of the CoSara PCR Pro point-of-care platform and SARAGENE product line, subject to regulatory approvals. The company is building regional distribution channels and positioning for broader deployment of its molecular diagnostics solutions across the newly added territories.
Co-Diagnostics, a molecular diagnostics company based in Utah, develops, manufactures and markets state-of-the-art diagnostics technologies. The company's technologies are utilized for tests designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). Co-Diagnostics also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform, which is subject to regulatory review and not currently for sale, and to identify genetic markers for use in applications other than infectious disease.
The press release noted that the full details are available at https://ibn.fm/2aATV. For more information about Co-Diagnostics, visit the company's website at https://co-dx.com/.
This expansion comes as Co-Diagnostics continues to build its presence in the global diagnostics market. The inclusion of Bangladesh, Pakistan, Nepal and Sri Lanka adds significant population centers and healthcare markets to CoSara's distribution network. The company's joint venture, CoSara Diagnostics Pvt. Ltd., is expected to leverage this expanded territory to drive adoption of its molecular diagnostics platforms.
The announcement highlights the strategic importance of the South Asian region for Co-Diagnostics' growth. With an estimated $13 billion addressable market, the expansion positions the company to capture a larger share of the molecular diagnostics market in these countries. However, the commercialization of the PCR Pro platform and SARAGENE product line is subject to regulatory approvals in each territory.
Co-Diagnostics' forward-looking statements caution that actual results may differ materially from those projected. Risks and uncertainties include those set forth in the company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The press release also includes disclaimers from the InvestorBrandNetwork, which can be found at http://IBN.fm/Disclaimer.
